In reply: espying sarcopenia in gastric cancer: squaring the circle
2024

Discussion on Sarcopenia in Gastric Cancer

Editorial

Author Information

Author(s): Chan Wing-Lok

Primary Institution: The University of Hong Kong

Hypothesis

Can sarcopenia, measured by skeletal muscle index, predict clinical outcomes in patients with advanced gastric cancer?

Conclusion

Prechemotherapy skeletal muscle index cut-off values can identify patients at higher risk of severe chemotherapy toxicities and worse prognosis.

Supporting Evidence

  • Prechemotherapy SMI cut-off values of ≤33 cm2/m2 for males and ≤28 cm2/m2 for females can identify high-risk patients.
  • Sarcopenia is linked to increased risk of falls, functional decline, and mortality.
  • Muscle ultrasound is a promising tool for assessing sarcopenia but has limitations compared to CT.

Takeaway

Doctors can use muscle size measurements to find out which cancer patients might have a harder time with treatment.

Methodology

The study examined the association between sarcopenia and clinical outcomes in patients with advanced gastric cancer using skeletal muscle index from CT scans.

Limitations

Ultrasound for assessing sarcopenia has limitations such as user-dependence and lack of standardized protocols.

Digital Object Identifier (DOI)

10.1093/oncolo/oyae232

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication